Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...8788899091929394959697...123124»
  • ||||||||||  Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Journal:  New Treatments Emerge for RCC. (Pubmed Central) -  Mar 12, 2021   
    In one, the combination of lenvatinib and pembrolizumab was superior to sunitinib and to lenvatinib plus everolimus in clear-cell RCC. In the other, cabozantinib was more effective than sunitinib in papillary RCC.
  • ||||||||||  Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Role of Immunotherapy in the Management of Hepatocellular Carcinoma: Current Standards and Future Directions. (Pubmed Central) -  Mar 12, 2021   
    Despite the impressive results and generally good toxicity profile of immunotherapy, patients who respond to therapy constitute only a subset of the overall population, and response rates are still limited. This review focuses on the currently reported results and ongoing clinical trials of checkpoint inhibitor-based immunotherapy in HCC.
  • ||||||||||  Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Metastases:  Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) -  Mar 3, 2021   
    P2,  N=32, Active, not recruiting, 
    In conclusion, the combination of lenvatinib with an MEK inhibitor is a potentially viable therapeutic approach for ATC treatment. Trial completion date: Dec 2020 --> Nov 2021
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial completion date, Trial primary completion date:  PEMMELA: Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (clinicaltrials.gov) -  Mar 3, 2021   
    P2,  N=36, Recruiting, 
    Trial completion date: Dec 2020 --> Nov 2021 Not yet recruiting --> Recruiting | Trial completion date: Feb 2021 --> Aug 2021 | Trial primary completion date: Feb 2021 --> Aug 2021
  • ||||||||||  Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Enrollment change, Tumor mutational burden, Metastases:  Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Mar 2, 2021   
    P2,  N=36, Recruiting, 
    Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | N=56 --> 36
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Trial completion date, Trial primary completion date:  Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer (clinicaltrials.gov) -  Feb 25, 2021   
    P1,  N=26, Active, not recruiting, 
    Trial completion date: Dec 2020 --> Mar 2022 Trial completion date: Nov 2019 --> Dec 2022 | Trial primary completion date: Nov 2019 --> Dec 2021